Zealand Pharma Nears EU Approval for Short Bowel Syndrome Treatment
Event summary
- CHMP recommends approval of Zeydovio™ (glepaglutide) for short bowel syndrome in Europe.
- Two-thirds of patients achieved at least 20% reduction in parenteral support volume.
- European Commission decision expected within 67 days.
- Phase 3 EASE-5 trial ongoing for U.S. regulatory submission.
The big picture
This positive CHMP opinion marks the first major advancement in short bowel syndrome treatment in Europe in over a decade. Zealand Pharma's glepaglutide represents a potential transformative therapy for a rare, chronic condition with significant unmet medical needs. The company's focus on metabolic health and peptide R&D positions it as a key player in developing next-generation treatments for complex gastrointestinal disorders.
What we're watching
- Regulatory Timing
- Whether the European Commission will approve Zeydovio™ within the expected 67-day window.
- Commercial Strategy
- How Zealand Pharma will structure global commercialization partnerships for glepaglutide.
- U.S. Market Entry
- The pace at which the Phase 3 EASE-5 trial will deliver data to support a U.S. NDA submission.
Related topics